Yifeng Pharmacy - Public Comps and Valuation Multiples

Yifeng Pharmacy Overview

About Yifeng Pharmacy

Yifeng Pharmacy Chain Co Ltd is mainly engaged in the chain retail business of medicines, health products, medical devices, and health-related daily convenience products. Its operating segments include the Retail segment and the Wholesale segment.

Founded

2008

HQ

Employees

40.0K+

Website

yfdyf.cn

Sectors

Pharmacies

Financials

LTM Revenue $3.5B

LTM EBITDA $421M

EV

$3.9B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Yifeng Pharmacy Financials

As of September 2025, Yifeng Pharmacy reported last 12-month revenue of $3.5B and EBITDA of $421M.

In the same period, Yifeng Pharmacy generated $1.4B in LTM gross profit and $239M in net income.

See Yifeng Pharmacy valuation multiples based on analyst estimates

Yifeng Pharmacy P&L

In the most recent fiscal year, Yifeng Pharmacy reported revenue of $3.4B and EBITDA of $601M.

Yifeng Pharmacy expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Yifeng Pharmacy valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$3.5B	XXX	$3.4B	XXX	XXX	XXX
Gross Profit	$1.4B	XXX	$1.4B	XXX	XXX	XXX
Gross Margin	40%	XXX	40%	XXX	XXX	XXX
EBITDA	$421M	XXX	$601M	XXX	XXX	XXX
EBITDA Margin	12%	XXX	18%	XXX	XXX	XXX
EBIT	$354M	XXX	$325M	XXX	XXX	XXX
EBIT Margin	10%	XXX	10%	XXX	XXX	XXX
Net Profit	$239M	XXX	$214M	XXX	XXX	XXX
Net Margin	7%	XXX	6%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Yifeng Pharmacy including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $3.5B. EBITDA for the last twelve months was $421M. In the most recent fiscal year, Yifeng Pharmacy achieved $3.4B in revenue and $601M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$3.5B	Analyst estimates available to subscribers	$3.4B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.4B	Analyst estimates available to subscribers	$1.4B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	40.3% gross margin	Analyst estimates available to subscribers	40.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$421M	Analyst estimates available to subscribers	$601M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	11.9% EBITDA margin	Analyst estimates available to subscribers	17.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$354M	Analyst estimates available to subscribers	$325M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	10.0% EBIT margin	Analyst estimates available to subscribers	9.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$239M	Analyst estimates available to subscribers	$214M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	6.8% net profit margin	Analyst estimates available to subscribers	6.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Yifeng Pharmacy

This financial data table provides comprehensive performance metrics for Yifeng Pharmacy, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Yifeng Pharmacy generated $3.5B in revenue over the last twelve months.
The company achieved $421M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.4B.
Net income over the last twelve months reached $239M.

Fiscal Year Performance

In the most recent fiscal year, Yifeng Pharmacy reported $3.4B in total revenue.
Fiscal year EBITDA was $601M.
The company maintained a gross profit margin of 40.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 17.8%.
Net profit margin reached 6.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Yifeng Pharmacy. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Yifeng Pharmacy Stock Performance

Yifeng Pharmacy has current market cap of CNY 30.9B (or $4.3B), and EV of CNY 28.1B (or $3.9B).

Market Cap Evolution

Yifeng Pharmacy Stock Data

As of October 30, 2025, Yifeng Pharmacy's stock price is CNY 25 (or $4).

See Yifeng Pharmacy trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.9B	$4.3B	XXX	XXX	XXX	XXX	$0.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Yifeng Pharmacy Valuation Multiples

Yifeng Pharmacy's trades at 1.2x EV/Revenue multiple, and 6.5x EV/EBITDA.

See valuation multiples for Yifeng Pharmacy and 15K+ public comps

Yifeng Pharmacy Financial Valuation Multiples

As of October 30, 2025, Yifeng Pharmacy has market cap of $4.3B and EV of $3.9B.

Equity research analysts estimate Yifeng Pharmacy's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Yifeng Pharmacy has a P/E ratio of 18.1x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$4.3B	XXX	$4.3B	XXX	XXX	XXX
EV (current)	$3.9B	XXX	$3.9B	XXX	XXX	XXX
EV/Revenue	1.1x	XXX	1.2x	XXX	XXX	XXX
EV/EBITDA	9.3x	XXX	6.5x	XXX	XXX	XXX
EV/EBIT	11.1x	XXX	12.1x	XXX	XXX	XXX
EV/Gross Profit	2.8x	XXX	n/a	XXX	XXX	XXX
P/E	18.1x	XXX	20.2x	XXX	XXX	XXX
EV/FCF	15.3x	XXX	7.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Yifeng Pharmacy Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Yifeng Pharmacy Margins & Growth Rates

Yifeng Pharmacy's last 12 month revenue growth is 10%

Yifeng Pharmacy's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $26K for the same period.

Yifeng Pharmacy's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Yifeng Pharmacy's rule of X is 36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Yifeng Pharmacy and other 15K+ public comps

Yifeng Pharmacy Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	10%	XXX	8%	XXX	XXX	XXX
EBITDA Margin	12%	XXX	18%	XXX	XXX	XXX
EBITDA Growth	11%	XXX	-11%	XXX	XXX	XXX
Rule of 40	27%	XXX	28%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	36%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$26K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	30%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial